1. Market Research
  2. > Therapy Industry

Immunotherapy Industry, July 2016 Market Reports from Top Publishers

You might be interested in: Therapy, Bladder Cancer, Oncology, Ovarian Cancer, Cancer, Prostate Cancer, Breast Cancer, Colorectal Cancer, Nuclear Medicine, Pancreatic Cancer, Renal Cancer, Respiratory Disease, Blood Disease, Brain Cancer, Diabetes, Lymphoma, Respiratory Treatment, Transdermal Delivery, Allergy Immunotherapy, Anti-Infective.


 
1-10 of 68 reports for Immunotherapy

Purchase Reports From Reputable Market Research Publishers

T-cell Immunotherapy: Clinical Trial Tracker

T-cell Immunotherapy: Clinical Trial Tracker

  • $ 949
  • Industry report
  • July 2016
  • by Roots Analysis Private Ltd.

INTRODUCTION After years of research tracing back to the 18th century, a gamut of novel therapies namely, CAR-T, TCR and TIL therapies, have finally reached a point of maturity. These promising therapeutic ...

GLOBAL & USA CANCER IMMUNOTHERAPY MARKET ANALYSIS TO 2020: Antibody Drug Conjugates , Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor  T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Checkpoint

GLOBAL & USA CANCER IMMUNOTHERAPY MARKET ANALYSIS TO 2020: Antibody Drug Conjugates , Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Checkpoint

  • $ 3 800
  • Industry report
  • July 2016
  • by Kelly Scientific Publications

This report provides a comprehensive overview of the size of cancer immunotherapy market, the segmentation of the market, key players and the vast potential of therapies that are in clinical trials. Oncologic ...

Global Allergy Immunotherapies Market 2016-2020

Global Allergy Immunotherapies Market 2016-2020

  • $ 2 500
  • Industry report
  • July 2016
  • by Infiniti Research Limited

About the Allergy Immunotherapies Market Immunotherapy, often referred to as desensitization, is the closest thing to a cure for allergic diseases and is an established treatment for severe allergies such ...

Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) - Pipeline Review, H1 2016

Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) - Pipeline Review, H1 2016

  • $ 3 500
  • Company report
  • June 2016
  • by Global Markets Direct

Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Mucin 1 (MUC-1 or Breast Carcinoma-Associated ...

Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H1 2016

Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H1 2016

  • $ 3 500
  • Company report
  • June 2016
  • by Global Markets Direct

Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ...

Human Papilloma Virus (HPV) E7 Protein - Pipeline Review, H1 2016

Human Papilloma Virus (HPV) E7 Protein - Pipeline Review, H1 2016

  • $ 3 500
  • Company report
  • June 2016
  • by Global Markets Direct

Human Papilloma Virus (HPV) E7 Protein - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Human Papilloma Virus (HPV) E7 Protein - Pipeline Review, H1 2016’, provides in depth analysis ...

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H1 2016

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H1 2016

  • $ 3 500
  • Company report
  • June 2016
  • by Global Markets Direct

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ...

Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Review, H1 2016

Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Review, H1 2016

  • $ 3 500
  • Company report
  • June 2016
  • by Global Markets Direct

Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 ...

Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2016

Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2016

  • $ 42 521
  • Company report
  • May 2016
  • by Global Markets Direct

Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2016’, provides an overview of ...

Pneumonia Treatment Drugs Industry Forecasts - China Focus

Pneumonia Treatment Drugs Industry Forecasts - China Focus

  • $ 1 000
  • Industry report
  • May 2016
  • by Asia Market Information & Development Company

This study focuses on China’s Pneumonia Treatment Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities ...

About 3 400 reports for Immunotherapy

Download Unlimited Documents from Trusted Public Sources

Inovio Pharmaceuticals, Inc. - Annual Report, March 2015

  • March 2015
    100 pages
  • Immunotherapy  

    Electroporation  

    Vaccine  

  • United States  

View report >

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.